// App-Quantinova.ai

OP0126 (2021) : INFECTIONS AND SERIOUS INFECTIONS IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

Researchers

Presenter

  • J. Galloway

Principal Investigators

  • M. H. Buch

  • K. Yamaoka

  • A. Pechonkina

  • D. Jiang

  • L. Ye

  • R. Besuyen

  • D. Aletaha

  • K. Winthrop

Medical Centers

  • King’s College London, Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, London, United Kingdom

  • School of Biological Sciences The University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom

  • Kitasato University School of Medicine, Department of Rheumatology and Infectious Diseases, Sagamihara, Japan

  • Gilead Sciences, Inc., Clinical Development, Foster City, United States of America

  • Gilead Sciences, Inc., Biostatistics, Foster City, United States of America

  • Galapagos BV, Clinical Development, Leiden, Netherlands

  • Medical University of Vienna Clinical Division of Oncology, Department of Medicine, Vienna, Austria

  • Oregon Health and Science University, Division of Infectious Diseases, Portland, United States of America

Locations

  • United Kingdom

  • Japan

  • United States

  • Netherlands

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Infectious Diseases (ID)

Disease

  • Rheumatoid arthritis

  • Tuberculosis

  • Inflammatory Arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Methotrexate

  • Adalimumab

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Active Comparator

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved